Aegerion Pharmaceuticals Given New $40.00 Price Target at Jefferies Group (AEGR)
“Wider 4Q12 loss of $22M on higher OpEx (vs. our estimate). To date 85 NRx written for Juxtapid (translating into $2M in sales once shipped, ~3-4 months following written Rx). AEGR is confident 250-300 pts on therapy by YE13 and cash flow breakeven in 2H14 at ~$100M revenue runrate (vs. our estimate of 1H15). Potential near-term risk includes failure to gain EU approval (decision in ~mid-2013) or narrower label (vs. U.S.).,” the firm’s analyst commented.
Several other analysts have also recently commented on the stock. Analysts at Bank of America initiated coverage on shares of Aegerion Pharmaceuticals in a research note to investors on Tuesday. They set a buy rating and a $39.00 price target on the stock. Separately, analysts at Lazard Capital Markets upgraded shares of Aegerion Pharmaceuticals from a neutral rating to a buy rating in a research note to investors on Monday, February 11th. Finally, analysts at Deutsche Bank raised their price target on shares of Aegerion Pharmaceuticals from $30.00 to $37.00 in a research note to investors on Monday, January 28th. They now have a buy rating on the stock.
Aegerion Pharmaceuticals traded up 1.04% on Wednesday, hitting $35.88. Aegerion Pharmaceuticals has a 1-year low of $11.75 and a 1-year high of $37.10. The stock’s 50-day moving average is currently $28.97. The company’s market cap is $914.1 million.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.